Abstract
Infection of Shiga toxin (Stx)-producing Escherichia coli induces hemolytic uremic syndrome (HUS) in 10 to 15% of cases in infants and young children. Although the endothelial cell damage induced by Stx is widely believed to be a primary event of renal dysfunction in HUS, the precise mechanism remains to be elucidated. We were able to examine the kidney obtained at autopsy of a child who died after HUS associated with Stx-producing Escherichia coli O157:H7 infection, and immunohistochemistry indicated the deposition of Stx1 and Stx2 in a portion of the distal tubular epithelia. To our knowledge, this is the first report to show the presence of Stx in human tissue of a patient with HUS, and the results obtained in this study provide evidence that Stx indeed migrates into the kidney and binds to renal tubules during Stx-producing Escherichia coli infection.
Similar content being viewed by others
Main
HUS, a clinical syndrome consisting of hemolytic anemia, acute renal failure, and thrombocytopenia, is a major cause of pediatric acute renal failure(1). The pathogenetic status of HUS is preceded by a prodrome of bloody diarrhea in infants and young children(2). Since the beginning of the 1980s, it has been reported that STEC infections are the main cause of HUS(2,3).
Stx, also called verotoxin, was first discovered as a novel cytotoxin in vero cells, which were derived from the kidney of the African green monkey(4). Since the prototype toxin Stx1 was purified in 1983(5), two types of Stx, Stx1 and Stx2, and two Stx2 variants (subtypes), Stx2vh and Stx2vp, have been identified(6). The Stx are a complex of proteins consisting of A and B subunits(6). The A subunit is a 30-kD cytotoxic chain, which has ribonucleic acid N-glycohydrolase activity and cleaves a specific adenine residue on the 28S ribosomal ribonucleic acid, resulting in inhibition of protein synthesis(7–10). The 7-kD B subunit forms a pentamer and binds to the terminal digalactose of Gb3/CD77, a functional receptor for Stx(11–13), with high affinity(7,14). It is thought that the holotoxin binds via B subunits to the cells expressing its receptor Gb3/CD77, is internalized, and then damages the cells via inhibition of protein synthesis by the A subunit(7).
Based on experimental(15–19) and histopathologic observations(20), it is widely believed that endothelial cell damage mediated by Stx plays a central role in HUS(15,21). However, recent studies have shown that a specific portion of tubules(22,23) and glomeruler mesangial cells(24) express receptor and bind to Stx as well as endothelium. In addition, we have recently found that distal tubular epithelial cells in the kidney express Gb3/CD77 and are susceptible to Stx-mediated cytotoxicity via apoptosis(25,26). These findings suggest that endothelial cells are not the sole target for Stx-mediated cell injury.
Although experimental data indicate Stx-mediated direct injury of a variety of cell species in the kidney(5,15–19,21,24–27), details of the pathogenesis of HUS remain unclear largely because the kinetics of Stx in humans is not known. Although Stx, secreted by STEC in intestine, is thought to migrate to the kidney via blood flow, direct evidence has not been demonstrated that shows the presence of Stx either in the blood flow or in the damaged organ(3,27).
In this study, we used immunohistochemistry to detect the presence of residual Stx1 and Stx2 in the renal sections of an autopsied fatal case of HUS. Stx was found to bind to the specific portion of distal tubules. Our results suggest that during STEC infection, Stx migrates to the kidney from the intestine and binds to renal tubular epithelium, a target of Stx.
METHODS
Case presentation. A 1-y 9-mo-old girl primarily showed enteric symptoms of diarrhea and fever (38 °C) on July 16, 1996. On the 2nd d of the disease, bloody diarrhea occurred. On d 6 of the disease, enterocolitis progressed to HUS consisting of hemolytic anemia, thrombocytopenia, and symptoms of renal failure (severe edema, anuria, and hypertension), and the patient was therefore admitted to the hospital for intensive care. STEC O157:H7 (Stx1 +, Stx2+) was isolated in stool culture on d 3 and 7 of the disease. Peritoneal dialysis was performed during her entire admission period. Her general condition remained stable, although anuria continued until she died. Peritonitis due to perforation of the gall bladder occurred and progressed to respiratory distress. The patient died in d 25. Renal function was not improved during her clinical course. Autopsy was performed, and renal tissue was frozen. Her laboratory data during admission are summarized in Table 1.
Immunohistochemical analysis. Frozen sections were prepared and fixed in 100% acetone at 4°C for 15 min. After washing with PBS and blocking with 5% normal rabbit serum for 20 min at room temperature, samples were overlaid with monoclonal anti-Stx1 (13C4, ECACC No. 95032701)(28) or anti-Stx2 antibody (VTm1.1)(29) for 30 min at room temperature. These anti-Stx antibodies were used at a 300-fold dilution of ascites forms. Isotype-matched mouse monoclonal immunoglobulin was used as a control. After washing with PBS, samples were treated with horseradish peroxidase-conjugated rabbit anti-mouse antibody (DAKO). A final wash with PBS was followed by color development using 3,3′ -diaminobenzidine, tetrahydrochloride as described previously(30). Expression of CD molecules on the renal tissue was detected by using anti-CD10 (IF-6)(31), anti-CD24 (L30)(32), anti-CD34 (QBEnd10, Coulter/Immunotec, Inc., Westbrook, MA), and anti-Gb3/CD77 (38.13, Coulter)(33) antibodies. The method of staining for CD molecules was identical to that described above. As negative control, six renal tissues from patients without HUS, including IgA nephropathy, nephrotic syndrome, and Wilms' tumor (nontumor part), were also examined. All materials were used after obtaining informed consent and have been approved by our Institutional Review Board.
RESULTS
Hematoxylin and eosin staining of renal sections showed focal necrosis (Fig. 1A) and tissue regeneration (Fig. 1, B and C). The regenerating tissue mostly consisted of small tubules (Fig. 1B), but dilated tubules could also be identified (Fig. 1C).
In frozen sections, an Stx1 MAb clearly stained epithelial cells of dilated tubules (Fig. 2A). With precise observation, it was evident that staining was mainly located on the apical portion of epithelia. Monoclonal anti-Stx2 antibody also stained the epithelia of dilated tubules with an identical staining pattern (Fig. 2C). No staining was observed by using an isotype-matched control antibody (Fig. 2D). Six kidney tissues obtained from patients without HUS were not stained by anti-Stx1 nor Stx2 (an example is presented in Fig. 2, E and F). Because the specificity of these antibodies has been confirmed previously(26,28,29, Uchida H et al., unpublished observations.), these results show the specific detection of Stx1 and Stx2 on the renal tubules. In addition to distal tubules, a few damaged glomeruli (Fig. 3A) and endothelia (Fig. 3, A and B) were also stained with anti-Stx antibodies.
It has been reported that the cellular components of the kidney can be classified according to the pattern of expression for CD leukocyte antigens(30,34–36). The renal distribution of CD molecules was tested to localize the sites of Stx binding. CD10 was reported to be expressed on glomeruler and proximal tubular epithelia(30,34). In the patient's tissue, CD10 was expressed on glomeruli and on proximal tubules that were twisted in shape (Fig. 4A). These CD10-positive tubules were mostly distributed around glomeruli in this specimen. In addition, no staining of CD10 was observed in dilated tubules (Fig. 4B), which were positive for Stx staining. In normal tissue, CD24 is expressed on a part of Henle's loop, distal tubules, and Bowman's capsule(30,35). In the patient's sample, CD24 was expressed on a considerable number of tubules (Fig. 4C) as well as on Bowman's capsules (data not shown). These CD24-positive tubules were mostly small, dilated, and round (Fig. 4D). Collecting tubules, which assembled to form a nest, were negative for CD24 (Fig. 4C). Gb3/CD77, a functional receptor for Stx(11–13), was expressed on dilated tubules and on some of the tubules that were small in diameter (Fig. 4F). It was thus likely that some of the CD24-positive tubules expressed Gb3/CD77. Gb3/CD77 was also positive on endothelial cells of small vessels. CD34 is a hematopoietic progenitor marker but is also known to be expressed on vascular endothelial cells(36). Consistent with this, small vessels were visualized by CD34 in the patient's kidney (Fig. 4E).
The sites of Stx binding could be specified in relation to the distributions of these CD molecules. It was thus apparent that there was no binding of either Stx1 or Stx2 on proximal tubules in the specimen because the patterns of distribution of Stx and CD10 were completely different. Rather, Stx was mostly localized to dilated distal tubules, which were positive for CD24 and Gb3/CD77.
DISCUSSION
We have shown the specific binding of anti-Stx1 and anti-Stx2 MAb to epithelia of a portion of tubules, which corresponded to distal tubules in the renal section of a patient with HUS with STEC infection. The reagents used in this investigation are highly specific, as confirmed previously (26,28,29, Uchida H et al., unpublished observations) and by the fact that control kidneys were not stained. Although it has been postulated that Stx produced by STEC in the intestine migrate into kidney via the blood stream(3,27) and then injure a variety of renal cell species(5,15–19,21,24–27,37), this has not been proven. To our knowledge, this is the first report describing the in situ immunostaining of Stx1 and Stx2 in the kidney of a patient with STEC infection, indicating that Stx migrates into the kidney during STEC infection.
The tubules on which Stx were deposited were characterized by comparing the distribution of various CD molecules. It was apparent that Stx bound to some of the cells that were positive for CD24, a marker for the ascending part of Henle's loop, and distal tubules(30,35). In addition, Stx staining was clearly positive on some of the tubular epithelial cells that expressed Gb3/CD77, a functional receptor for Stx(11–13). It has been reported that tubular epithelia expressed Gb3/CD77 and bound Stx(22,23), although this relationship was not described precisely. The Gb3/CD77-positive tubules were similar to the CD24-positive ones in this case. Thus, it is likely that a portion of distal tubules expressed Gb3/CD77. Our preliminary study on normal renal tissue obtained from children with Wilms' tumor also indicated that a portion of CD24-positive epithelia expresses Gb3/CD77 and binds Stx (Mori T et al., unpublished observations). These data correlate with our previous report that Stx can bind to cells derived from distal tubular epithelial cells in the kidney and directly injure them via induction of apoptosis(25,26), suggesting that the distal tubule is another primary target for Stx.
Certain important questions arise from our observations. Were Stx-bound tubules in this sample undergoing cellular damage? Is it really possible for Stx to be detected so late? We cannot currently address these questions. Indeed, it is curious that Stx was detected on tissue obtained as late as d 25 of the patient's illness because it is unlikely that STEC was still present. In addition, most of the cells should be destroyed if they were attached to the toxin. Although we did not have a chance to examine the patient's renal tissue at the early stage of her disease, the laboratory data suggest that the kidney was severely damaged and the histologic examination showed considerable regeneration at autopsy.
One possible interpretation concerning the unresponsiveness of the cells to toxin may be that Stx can bind to Gb3/CD77 on cells but is not internalized. Details of this mechanism are still unknown, but the following reports may support this idea. First, Jacewicz et al.(38) reported that Gb3/CD77 is required for Stx binding but not sufficient for cytotoxicity and suggested the existence of a toxin translocation mechanism linked to surface glycolipids. Thus, Stx binding without internalization could be possible where the toxin translocation mechanism is absent or dysfunctional while Stx receptor is present. Second, it was reported that Gb3/CD77 receptors have fatty acid heterogeneity, which modulates receptor function(39–41). Thus, the diversity of Gb3/CD77 receptors may account for the different behavior of Stx after binding. It was reported that Stx1 binds to human monocytes or mouse peritoneal macrophages via a Gb3/CD77 species that is different from that found on endothelial cells and induces cytokine synthesis but not cell death(42,43). In addition, the cytotoxic effect of Stx does not always parallel the expression level of Gb3/CD77 receptors and Stx binding. For example, it is well known that HUS due to STEC infection occurs more frequently in infants and young children than in adults among the patients, even though the total renal contents of Gb3/CD77 is lower in children and the binding capacity of Stx is proportional to the level of Gb3/CD77 expression(44). Moreover, we also reported a significant difference between Stx1 and Stx2 in terms of efficiency for cytotoxicity in ACHN cells even though their binding affinity to ACHN cells is comparable(25).
Taken together, these results suggest that a small level of Gb3/CD77 receptor heterogeneity may affect the internalization efficiency of Stx. If this is the case, Stx may bind to renal tubular cells that express Gb3/CD77 but fail to be internalized in some cells. Although further study must be conducted, the determination of the mechanism of internalization of Stx after binding to the cell surface, especially as this relates to Gb3/CD77 receptor diversity, should provide new direction of research as well as of clinical management to overcome this disorder, HUS.
Abbreviations
- HUS:
-
hemolytic uremic syndrome
- STEC:
-
Shiga toxin-producing Escherichia coli
- Stx:
-
Shiga toxin
- Gb3:
-
globotriaosylceramide
- CD:
-
cluster of differentiation
References
Fong JS, de Chadarevian JP, Kaplan BS 1982 Hemolytic uremic syndrome: current concepts and management. Pediatr Clin North Am 29: 835–856.
Karmali MA, Petric M, Lim C, Fleming DC, Arbus GS, Lior H 1985 The association between idiopathic hemolytic uremic syndrome and infection by verotoxin producing Escherichia coli. J Infect Dis 151: 775–782.
Karmali MA, Steele BT, Petric M, Lim C 1983 Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Echerichia coli. Lancet 1: 619–620.
Konowalchuk J, Speirs JI, Stavric S 1977 Vero response to a cytotoxin of Escherichia coli. Infect Immun 18: 775–779.
O'Brien AD, LaVeck GD 1983 Purification and characterization of a Shigella dysenteriae 1-like toxin produced by Escherichia coli. Infect Immun 40: 675–683.
Lingwood CA 1993 Verotoxins and their glycolipid receptors. Adv Lipid Res 25: 189–212.
Donohue-Rolfe A, Keusch GT, Edson C, Thorley-Lawson D, Jacewicz M 1984 Pathogenesis of Shigella diarrhea: IX: simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies. J Exp Med 160: 1767–1781.
Obrig TG, Moran TP, Brown JE 1987 The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 244: 287–294.
Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K 1988 Site of action of a verotoxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes: RNA N-glycosidase activity of the toxins. Eur J Biochem 171: 45–50.
Saxena SK, O'Brien AD, Ackerman EJ 1989 Shiga toxin, Shiga-like II variant, and ricin are all single-site RNA N-glycosidases of 28S RNA when microinjected into Xenopus oocytes. J Biol Chem 264: 596–601.
Jacewicz M, Clausen H, Nudelman E, Donohue-Rolfe A, Keusch GT 1986 Pathogenesis of Shigella diarrhea: XI: Isolation of a Shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med 163: 1391–1404.
Lindberg AA, Brown JE, Stromberg N, Westling-Ryd M, Schultz JE, Karlsson KA 1987 Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J Biol Chem 262: 1779–1785.
Lingwood CA, Law H, Richardson S, Petric M, Brunton JL, De Grandis S, Karmali M 1987 Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem 262: 8834–8839.
Nyholm PG, Bruton JL, Lingwood CA 1995 Modelling of the interaction of verotoxin-1 (VT1) with its glycolipid receptor, globotriaosylceramide (Gb3). Int J Biol Macromol 17: 199–204.
Obrig TG, Del Vecchio PJ, Brown JE, Moran TP, Rowland BM, Judge TK, Rothman SW 1988 Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun 56: 2373–2378.
Tesh VL, Samuel JE, Perera LP, Sharefkin JB, O'Brien AD 1991 Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J Infect Dis 164: 344–352.
Kaye SA, Louise CB, Boyd B, Lingwood CA, Obrig TG 1993 Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun 16: 3886–3891.
Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO 1993 Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 268: 15484–15488.
van Setten PA, van Hinsbergh VW, van der Verden TJ, van de Kar NC, Vermeer M, Mahan JD, Assmann KJ, van den Heuvel LP, Monnens LA 1997 Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular endothelial cells. Kidney Int 51: 1245–1256.
Richardson SE, Karmali MA, Becker LE, Smith CR 1988 The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol 19: 1102–1108.
Kaplan BS, Cleary TG, Obrig TG 1990 Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes. Pediatr Nephrol 4: 276–283.
Lingwood CA 1994 Verotoxin-binding in human renal sections. Nephron 60: 21–28.
Oosterwijk E, Kalisiak A, Wakka JC, Scheinberg DA, Old LJ 1991 Monoclonal antibodies against Gal alpha 1:4 Gal beta 1-4 Glc (pk, CD77) produced with a synthetic glycoconjugate as immunogen: reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors. Int J Cancer 48: 848–54.
Robinson LA, Hurley RM, Lingwood CA, Matsell DG 1995 Escherichia coli verotoxin binding to human paediatric glomerular mesangial cells. Pediatr Nephrol 9: 700–704.
Taguchi T, Uchida H, Kiyokawa N, Mori T, Sato N, Horie H, Takeda T, Fujimoto J 1998 Verotoxins induce apoptosis in human renal tubular epithelium derived cells. Kidney Int 53: 1681–1688.
Kiyokawa N, Taguchi T, Mori T, Uchida H, Sato N, Takeda T, Fujimoto J 1998 Induction of apoptosis in normal human renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. J Infect Dis 178: 178–184.
Keusch GT, Acheson DW, Aaldering L, Erban J, Jacewicz MS 1996 Comparison of effects of Shiga-like toxin 1 on cytokine- and butyrate-treated human umbilical and saphenous vein endothelial cells. J Infect Dis 173: 1164–1170.
Strockbine NA, Marques LR, Holmes RK, O'Brien AD 1985 Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun 50: 695–700.
Yoshikawa K, Yoshino K, Hayashi S, Yamasaki S, Kimura T, Matsumoto Y, Imaizumi A, Takeda T 1997 Epitope analysis of a mouse monoclonal antibody against Stx2. Abstract of 78th Annual Meeting of Japanese Society for Bacteriology Kanto Branch, p 17
Ishii E, Fujimoto J, Tanaka S, Hata J 1987 Immunohistochemical analysis on normal nephrogenesis and Wilms' tumor using monoclonal antibodies reactive with lymphohaemopoietic antigens. Virchows Arch 411: 315–322.
Fujimoto J, Ishimoto K, Kiyokawa N, Tanaka S, Ishii E, Hata J 1988 Immunocytological and immunochemical analysis on common acute lymphoblastic leukemia antigen (CALLA): evidence that CALLA on ALL cells and granulocytes are structurally related. Hybridoma 7: 227–236.
Kokai Y, Ishii Y, Kikuchi K 1986 Characterization of two distinct antigens expressed on either resting or activated human B cells as defined by monoclonal antibodies. Clin Exp Immunol 64: 382–391.
Nudelman E, Kannagi R, Hakomori S, Parsons M, Lipinski M, Wiels J, Fellous M, Tursz T 1983 A glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody. Science 220: 509–511.
Metzgar RS, Borowitz MJ, Jones NH, Dowell BL 1981 Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues. J Exp Med 154: 1249–1254.
Platt JL, LeBien TW, Michael AF 1983 Stages of renal ontogenesis identified by monoclonal antibodies reactive with lymphohemopoietic differentiation antigens. J Exp Med 157: 155–172.
Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, Sutherland DR, Baker MA, Greaves MF 1990 Expression of the CD34 gene in vascular endothelial cells. Blood 75: 2417–2426.
Takeda T, Dohi S, Igarashi T, Yoshiya K, Kobayashi N 1993 Impairment by verotoxin of tubular function contributes to the renal damage seen in haemolytic uremic syndrome. J Infect 27: 339–341.
Jacewicz MS, Mobassaleh M, Gross SK, Balasubramanian KA, Daniel PF, Raghavan S, McCluer RH, Keusch GT 1994 Pathogenesis of Shigella diarrhea: XVII: a mammalian cell membrane glycolipid, Gb3, is required but not sufficient to confer sensitivity to Shiga toxin. J Infect Dis 169: 538–546.
Pellizzari A, Pang H, Lingwood CA 1992 Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochemistry 31: 1363–1370.
Boyd B, Magnusson G, Zhiuyan Z, Lingwood CA 1994 Lipid modulation of glycolipid receptor function: availability of Gal (alpha 1:4) Gal disaccharide for verotoxin binding in natural and synthetic glycolipids. Eur J Biochem 223: 873–878.
Kiarash A, Boyd B, Lingwood CA 1994 Glycosphingolipid receptor function is modified by fatty acid content: verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosylceramide fatty acid homologues. J Biol Chem 269: 11138–11146.
Tesh VL, Ramegowda B, Samuel JE 1994 Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect Immun 62: 5085–5094.
van Setten PA, Monnens LA, Verstraten RG, van den Heuvel LP, van Hinsberg VW 1996 Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 88: 174–183.
Boyd B, Lingwood CA 1989 Verotoxin receptor glycolipid in human renal tissue. Nephron 51: 207–210.
Acknowledgements
The authors thank Dr. K. Yan (Kyorin University), Dr. Y. Komatsu and Dr. Y. McParland (Chiba Children's Hospital) for providing materials in this study.
Author information
Authors and Affiliations
Additional information
This work was supported by the Program for Promotion of Fundamental Studies in Health Sciences of the Organization for Drug ADR Relief, R&D Promotion and Product Review of Japan, Ministry of Health and Welfare, and Japan Health Sciences Foundation.
Rights and permissions
About this article
Cite this article
Uchida, H., Kiyokawa, N., Horie, H. et al. The Detection of Shiga Toxins in the Kidney of a Patient with Hemolytic Uremic Syndrome. Pediatr Res 45, 133–137 (1999). https://doi.org/10.1203/00006450-199901000-00022
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199901000-00022
This article is cited by
-
LPS-primed CD11b+ leukocytes serve as an effective carrier of Shiga toxin 2 to cause hemolytic uremic syndrome in mice
Scientific Reports (2018)
-
Renal and neurological involvement in typical Shiga toxin-associated HUS
Nature Reviews Nephrology (2012)